Research Analysts Issue Forecasts for NBIX FY2026 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report released on Tuesday, April 22nd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $4.33 per share for the year, down from their prior forecast of $4.43. HC Wainwright has a "Buy" rating and a $168.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences' FY2027 earnings at $7.09 EPS and FY2029 earnings at $14.31 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

NBIX has been the subject of several other reports. William Blair reaffirmed an "outperform" rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Needham & Company LLC raised shares of Neurocrine Biosciences from a "hold" rating to a "buy" rating and set a $138.00 price objective on the stock in a report on Tuesday, April 15th. Royal Bank of Canada upgraded Neurocrine Biosciences from a "sector perform" rating to an "outperform" rating and reduced their target price for the stock from $138.00 to $137.00 in a research note on Monday, April 14th. Deutsche Bank Aktiengesellschaft started coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a "hold" rating and a $138.00 price target on the stock. Finally, Bank of America decreased their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $161.09.

Neurocrine Biosciences Trading Up 1.1 %

NASDAQ NBIX opened at $101.74 on Wednesday. The firm has a market capitalization of $10.07 billion, a P/E ratio of 30.92, a P/E/G ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $157.98. The firm's fifty day simple moving average is $107.72 and its two-hundred day simple moving average is $122.29.

Neurocrine Biosciences announced that its Board of Directors has initiated a share buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Insider Activity

In related news, Director Kevin Charles Gorman sold 146,105 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the completion of the sale, the director now directly owns 514,596 shares in the company, valued at approximately $76,911,518.16. The trade was a 22.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 623 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the transaction, the insider now directly owns 3,442 shares of the company's stock, valued at approximately $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 167,906 shares of company stock worth $24,671,530 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Several large investors have recently bought and sold shares of the business. Golden State Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Huntington National Bank boosted its stake in Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after buying an additional 97 shares during the last quarter. Brooklyn Investment Group grew its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after buying an additional 115 shares in the last quarter. GeoWealth Management LLC increased its stake in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Neurocrine Biosciences by 404.9% during the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company's stock worth $45,000 after acquiring an additional 328 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.